Acumen Pharmaceuticals (NASDAQ: ABOS)
1 known investors
Find your way into Acumen Pharmaceuticals (NASDAQ: ABOS)
305 people in our graph share verified history with the Acumen Pharmaceuticals (NASDAQ: ABOS) team — schools, employers, funds. One of them is your warm intro.
Josh Wolfeunlockedknows Derek Meisner · together at Genocea Biosciences (overlapped)
×2knows the team · via RA Capital
×3knows the team · via U.S. Securities and Exchange Commission
knows the team · via Genocea Biosciences
×2knows the team · via University of Cincinnati Carl H. Lindner College of Business
×2knows the team · via Indiana University School of Medicine
Acumen Pharmaceuticals is developing treatments for Alzheimer's disease and other neurodegenerative diseases, focusing on understanding and targeting amyloid beta oligomers in neurodegeneration.
Founders & leadership
DO
Daniel O'ConnellinFounder
JD
Jim Doherty, PhD
ES
Eric Siemers, MDinDr. Eric Siemers, an MD with over two decades of experience in neurodegenerative disease research across academia and industry, is Chief Medical Officer of Acumen Pharmaceuticals, where he specializes in clinical trial design and biomarkers for conditions including Alzheimer's, Parkinson's, and Huntington's disease.
MZ
Matthew Zuga
RB
Russell Barton, MS
AS
Amy Schacterle, PhD
DM
Derek MeisnerinDerek Meisner is a corporate executive with background in legal, operational, and compliance matters. He previously served as a partner at an international law firm and as Branch Chief at the U.S. Securities and Exchange Commission.
JB
Julie BockenstetteinJulie Bockenstette began her pharmaceutical career as a sales representative before transitioning to human resources, where she has held roles spanning employee relations, compensation, talent management, and global HR transformation initiatives at organizations with thousands of employees.
LS
Liean Schenck, MS
Investors · 1
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $222.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $176.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $183.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $145.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Acumen Pharmaceuticals (NASDAQ: ABOS) do?
- Acumen Pharmaceuticals is developing treatments for Alzheimer's disease and other neurodegenerative diseases, focusing on understanding and targeting amyloid beta oligomers in neurodegeneration.
- Who are Acumen Pharmaceuticals (NASDAQ: ABOS)'s investors?
- Acumen Pharmaceuticals (NASDAQ: ABOS)'s investors include K2 HealthVentures.